Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females age ≥ 18 years;~2. Histopathologically documented primary or secondary AML, as defined by WHO criteria (Jaffe et al, 2001), confirmed by pathology review at treating institution, meeting at least one of the following:~   1. Refractory to at least 1 cycle of induction chemotherapy, or~  2. Relapsed after at least 1 cycle of induction chemotherapy, or~  3. Patient is not, according to the clinical judgment of the Principal Investigator, a candidate for induction chemotherapy due to age, comorbidity, or other factors;~3. Patients for whom no standard therapies are anticipated to result in a durable remission, or who have failed potentially curative therapy, or who refuse standard therapy or patients for whom there is no known therapy of documented treatment benefit;~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3;~5. In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration should be at least 2 weeks for cytotoxic agents (other than hydroxyurea, per Section 8.8), or at least 5 half-lives for noncytotoxic agents;~6. Persistent chronic clinically significant toxicities from prior chemotherapy or surgery must be less than Grade 2;~7. Serum creatinine ≤ 2.0 mg/dL;~8. Total serum bilirubin ≤ 1.5 × ULN unless considered due to Gilbert's syndrome or leukemic organ involvement;~9. Serum AST or ALT ≤ 3.0 × ULN unless considered due to leukemic organ involvement;~10. Females of childbearing potential must have a negative pregnancy test (urine β-hCG);~11. Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study;~12. Written informed consent must be provided.~Exclusion Criteria:~1. Histologic diagnosis of acute promyelocytic leukemia;~2. Clinically active central nervous system leukemia;~3. Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or higher by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v3);~4. Bone marrow transplant within 2 months prior to study;~5. Active, uncontrolled infection;~6. Major surgery within 4 weeks prior to study;~7. Radiation therapy within 4 weeks prior to, or concurrent with, study;~8. Human immunodeficiency virus positivity;~9. Active hepatitis B or C or other active liver disease;~10. Women who are pregnant, lactating, or unwilling to use contraception if of childbearing potential;~11. Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the judgment of the Principal Investigator, could jeopardize patient safety or interfere with the objectives of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AC220 (Type: EXPERIMENTAL): Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete